 |
|
CLINICIAN'S CORNER
Pharmacological Management to Reduce Exacerbations in Adults With Asthma
A Systematic Review and Meta-analysis
Don D. Sin, MD, MPH;
Jonathan Man, MD;
Heather Sharpe, MN;
Wen Qi Gan, MD, MSc;
S. F. Paul Man, MD
JAMA. 2004;292:367-376.
Context Over the last 2 decades, many new pharmacological agents have been introduced to reduce the growing morbidity associated with asthma, but the long-term effects of these agents on exacerbations are unclear.
Objective To systematically review and quantitatively synthesize the long-term effects of inhaled corticosteroids, long-acting  2 agonists, leukotriene pathway modifiers/receptor antagonists, and anti-IgE therapies on clinical outcomes and particular clinically relevant exacerbations in adult patients with chronic asthma.
Data Sources MEDLINE, EMBASE, and Cochrane databases were searched to identify relevant randomized controlled trials and systematic reviews published from January 1, 1980, to April 30, 2004. We identified additional studies by searching bibliographies of retrieved articles and contacting experts in the field.
Study Selection and Data Extraction Included trials were double-blind, had follow-up periods of at least 3 months, and contained data on exacerbations and/or forced expiratory volume in 1 second. The effects of interventions were compared with placebo, short-acting 2 agonists, or each other.
Data Synthesis Inhaled corticosteroids were most effective, reducing exacerbations by nearly 55% compared with placebo or short-acting 2 agonists (relative risk [RR], 0.46; 95% confidence interval [CI], 0.34-0.62; P<.001 for heterogeneity). Compared with placebo, the use of long-acting 2 agonists was associated with 25% fewer exacerbations (RR, 0.75; 95% CI, 0.64-0.88; P = .43 for heterogeneity); when added to inhaled corticosteroids, there was a 26% reduction above that achieved by steroid monotherapy (RR, 0.74; 95% CI, 0.61-0.91; P = .07 for heterogeneity). Combination therapy was associated with fewer exacerbations than was increasing the dose of inhaled corticosteroids (RR, 0.86; 95% CI, 0.76-0.96; P = .65 for heterogeneity). Compared with placebo, leukotriene modifiers/receptor antagonists reduced exacerbations by 41% (RR, 0.59; 95% CI, 0.49-0.71; P = .44 for heterogeneity) but were less effective than inhaled corticosteroids (RR, 1.72; 95% CI, 1.28-2.31; P = .91 for heterogeneity). Use of monoclonal anti-IgE antibodies with concomitant inhaled corticosteroid therapy was associated with 45% fewer exacerbations (RR, 0.55; 95% CI, 0.45-0.66; P = .15 for heterogeneity).
Conclusions Inhaled corticosteroids are the single most effective therapy for adult patients with asthma. However, for those unable or unwilling to take corticosteroids, the use of leukotriene modifiers/receptor agonists appears reasonable. Long-acting 2 agonists may be added to corticosteroids for those who remain symptomatic despite low-dose steroid therapy. Anti-IgE therapy may be considered as adjunctive therapy for young adults with asthma who have clear evidence of allergies and elevated serum IgE levels.
Author Affiliations: James Hogg iCAPTURE Center for Cardiovascular and Pulmonary Research (Drs Sin, Gan, and S.F.P. Man) and Department of Medicine (Pulmonary Division) (Drs Sin, J. Man, and S.F.P. Man), University of British Columbia, Vancouver; and Department of Medicine (Pulmonary Division), University of Alberta, Edmonton (Ms Sharpe).
RELATED ARTICLE
Adult Asthma
Janet M. Torpy, Cassio Lynm, and Richard M. Glass
JAMA. 2004;292(3):402.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
New asthma guidelines emphasize control, regular monitoring
LANG
Cleveland Clinic Journal of Medicine 2008;75:641-653.
ABSTRACT
| FULL TEXT
Biomarkers in COPD: Are We There Yet?
Sin and Man
Chest 2008;133:1296-1298.
FULL TEXT
Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review
Joos et al.
Thorax 2008;63:453-462.
ABSTRACT
| FULL TEXT
Improving Asthma Care Through Recertification: A Cluster Randomized Trial
Simpkins et al.
Arch Intern Med 2007;167:2240-2248.
ABSTRACT
| FULL TEXT
Asthma exacerbations {middle dot} 4: Prevention.
FitzGerald and Gibson
Thorax 2006;61:992-999.
ABSTRACT
| FULL TEXT
Follow-up After an Asthma Hospitalization: Who Can Prevent Subsequent Exacerbations?
Schatz and Camargo
Chest 2006;130:8-10.
FULL TEXT
Considerations in the long-term management of asthma in ambulatory patients
Williams
Am J Health Syst Pharm 2006;63:S14-S21.
ABSTRACT
| FULL TEXT
Exercise-Induced Bronchoconstriction in Athletes
Parsons and Mastronarde
Chest 2005;128:3966-3974.
ABSTRACT
| FULL TEXT
Leukotriene receptor antagonists - an update
DTB 2005;43:85-88.
ABSTRACT
| FULL TEXT
Airway smooth muscle tone modulates mechanically induced cytoskeletal stiffening and remodeling
Deng et al.
J. Appl. Physiol. 2005;99:634-641.
ABSTRACT
| FULL TEXT
Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers
Gibson
Eur Respir J 2005;25:397-399.
FULL TEXT
Review: long term use of common medications for asthma reduces exacerbations in adults
Small
Evid. Based Nurs. 2005;8:14-14.
FULL TEXT
Long-Term Asthma Therapies Reduce Exacerbations
JWatch Emergency Med. 2004;2004:2-2.
FULL TEXT
|
